Literature DB >> 25071340

Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis.

Bruno César da Silva1, Andre Castro Lyra1, Raquel Rocha1, Genoile Oliveira Santana1.   

Abstract

Ulcerative colitis (UC) is a chronic disease characterized by diffuse inflammation of the mucosa of the colon and rectum. The hallmark clinical symptom of UC is bloody diarrhea. The clinical course is marked by exacerbations and remissions, which may occur spontaneously or in response to treatment changes or intercurrent illnesses. UC is most commonly diagnosed in late adolescence or early adulthood, but it can occur at any age. The incidence of UC has increased worldwide over recent decades, especially in developing nations. In contrast, during this period, therapeutic advances have improved the life expectancy of patients, and there has been a decrease in the mortality rate over time. It is important to emphasize that there is considerable variability in the phenotypic presentation of UC. Within this context, certain clinical and demographic characteristics are useful in identifying patients who tend to have more severe evolution of the disease and a poor prognosis. In this group of patients, better clinical surveillance and more intensive therapy may change the natural course of the disease. The aim of this article was to review the epidemiology and demographic characteristics of UC and the factors that may be associated with its clinical prognosis.

Entities:  

Keywords:  Incidence; Predictive factors; Prevalence; Risk factors; Ulcerative colitis

Mesh:

Year:  2014        PMID: 25071340      PMCID: PMC4110577          DOI: 10.3748/wjg.v20.i28.9458

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  116 in total

1.  Clinical features and natural history of ulcerative colitis in Korea.

Authors:  Sang Hyoung Park; Young Min Kim; Suk-Kyun Yang; Sai-Hui Kim; Jeong-Sik Byeon; Seung-Jae Myung; Yun Kyung Cho; Chang-Sik Yu; Kwi-Sook Choi; Jun-Won Chung; Benjamin Kim; Kee Don Choi; Jin-Ho Kim
Journal:  Inflamm Bowel Dis       Date:  2007-03       Impact factor: 5.325

2.  Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2010-01-12       Impact factor: 10.864

3.  Extension of ulcerative colitis.

Authors:  Canan Alkim; Hüseyin Alkim; Ulkü Dağli; Erkan Parlak; Aysel Ulker; Burhan Sahın
Journal:  Turk J Gastroenterol       Date:  2011-08       Impact factor: 1.852

4.  Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Authors:  Achuthan Sourianarayanane; Gaurav Garg; Thomas H Smith; Mujtaba I Butt; Arthur J McCullough; Bo Shen
Journal:  J Crohns Colitis       Date:  2012-11-15       Impact factor: 9.071

5.  Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.

Authors:  Jason W Harper; Mika N Sinanan; Timothy L Zisman
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

6.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

7.  Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.

Authors:  G T Ho; H M Lee; G Brydon; T Ting; N Hare; H Drummond; A G Shand; D C Bartolo; R G Wilson; M G Dunlop; I D Arnott; J Satsangi
Journal:  Am J Gastroenterol       Date:  2009-02-17       Impact factor: 10.864

8.  Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease.

Authors:  H Yuhara; C Steinmaus; D Corley; J Koike; M Igarashi; T Suzuki; T Mine
Journal:  Aliment Pharmacol Ther       Date:  2013-04-02       Impact factor: 8.171

9.  Rising incidence of pediatric inflammatory bowel disease in Scotland.

Authors:  Paul Henderson; Richard Hansen; Fiona L Cameron; Kostas Gerasimidis; Pam Rogers; W Michael Bisset; Emma L Reynish; Hazel E Drummond; Niall H Anderson; Johan Van Limbergen; Richard K Russell; Jack Satsangi; David C Wilson
Journal:  Inflamm Bowel Dis       Date:  2011-06-17       Impact factor: 5.325

10.  Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease.

Authors:  C A Lamb; J C Mansfield
Journal:  Frontline Gastroenterol       Date:  2010-11-03
View more
  61 in total

1.  Downregulation of iNOS and elevation of cAMP mediate the anti-inflammatory effect of glabridin in rats with ulcerative colitis.

Authors:  Nahla E El-Ashmawy; Naglaa F Khedr; Hoda A El-Bahrawy; Samar A El-Adawy
Journal:  Inflammopharmacology       Date:  2017-07-13       Impact factor: 4.473

2.  Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use.

Authors:  Danielle Bargo; Theo Tritton; Joseph C Cappelleri; Marco DiBonaventura; Timothy W Smith; Takanori Tsuchiya; Sean Gardiner; Irene Modesto; Tim Holbrook; Daniel Bluff; Taku Kobayashi
Journal:  Inflamm Intest Dis       Date:  2021-11-17

3.  Integrative computational approach identifies immune-relevant biomarkers in ulcerative colitis.

Authors:  Tianzhen He; Kai Wang; Peng Zhao; Guanqun Zhu; Xinbao Yin; Yulian Zhang; Zongliang Zhang; Kai Zhao; Zhenlin Wang; Ke Wang
Journal:  FEBS Open Bio       Date:  2022-01-12       Impact factor: 2.693

4.  Identification of diagnostic signatures in ulcerative colitis patients via bioinformatic analysis integrated with machine learning.

Authors:  Jiajie Lu; Zhiyuan Wang; Munila Maimaiti; Wenjia Hui; Adilai Abudourexiti; Feng Gao
Journal:  Hum Cell       Date:  2021-11-03       Impact factor: 4.174

5.  Diverticular colitis with progression to ulcerative colitis after sigmoidectomy.

Authors:  Atsuyo Ikeda; Tsunekazu Mizushima; Yutaro Egashira; Hidekazu Takahashi; Norikatsu Miyoshi; Naotsugu Haraguchi; Taishi Hata; Chu Matsuda; Yuichiro Doki; Masaki Mori
Journal:  Clin J Gastroenterol       Date:  2017-11-21

6.  Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis.

Authors:  Faith D Ihekweazu; Tatiana Fofanova; Ryan Palacios; Avanthi Ajjarapu; Lina Karam; Adam M Vogel; J R Rodriguez; Richard Kellermayer
Journal:  J Pediatr Surg       Date:  2020-02-03       Impact factor: 2.545

7.  Cost of Illness in Inflammatory Bowel Disease.

Authors:  Nagesh Kamat; C Ganesh Pai; M Surulivel Rajan; Asha Kamath
Journal:  Dig Dis Sci       Date:  2017-08-01       Impact factor: 3.199

8.  Lizhong decoction ameliorates ulcerative colitis in mice via modulating gut microbiota and its metabolites.

Authors:  Junfeng Zou; Yumeng Shen; Mengjun Chen; Zhimiao Zhang; Suwei Xiao; Chen Liu; Yue Wan; Lei Yang; Shu Jiang; Erxin Shang; Dawei Qian; Jinao Duan
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-17       Impact factor: 4.813

9.  TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis.

Authors:  Bo Xiao; Qiubing Chen; Zhan Zhang; Lixin Wang; Yuejun Kang; Timothy Denning; Didier Merlin
Journal:  J Control Release       Date:  2018-08-11       Impact factor: 9.776

10.  Diosmetin has therapeutic efficacy in colitis regulating gut microbiota, inflammation, and oxidative stress via the circ-Sirt1/Sirt1 axis.

Authors:  Hai-Long Li; Yi-Ying Wei; Xiao-He Li; Shan-Shan Zhang; Ruo-Tong Zhang; Jin-He Li; Bo-Wei Ma; Shuai-Bo Shao; Zi-Wei Lv; Hao Ruan; Hong-Gang Zhou; Cheng Yang
Journal:  Acta Pharmacol Sin       Date:  2021-07-14       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.